Hypertension project at Sidec

- Last updated on GMT

Related tags: Protein

Sidec Technologies has entered into a contract research
collaboration with a US research institute to study a receptor
involved in the regulation of blood pressure.

Sweden's Sidec Technologies, a specialist in three-dimensional imaging, has entered into a contract research collaboration with the Cleveland Clinic Lerner Research Institute in the USA to study a receptor protein involved in the regulation of blood pressure.

"Hypertension is one of the leading causes of death throughout the world. Using a 3-D protein analysis to determine how the system in the body works to maintain optimal blood pressure may help in developing medications to the mimic and enhance those regulatory mechanisms,"​ said Kunio Misono, a scientist at the Lerner Research Institute and the project's principle investigator.

The target in question is the atrial natriuretic peptide receptor (ANPR), and Sidec​'s task will be to analyse and characterise the interaction between ANP, the natural ligand of the membrane-bound receptor, in order to help design drugs that can modulate its activity.

A relative of ANP, known as b-type natriuretic factor, is already on the market as a treatment for heart failure and is sold as Natrecor (nesiritide) by Scios.

Meanwhile, other clues to the potential of the ANP/ANPR interaction as a drug target in hypertension and other cardiovascular diseases comes from studies of established blood pressure-lowering drugs. For example, angiotensin II receptor antagonists - such as irbesartan sold by Sanofi-Synthelabo and Bristol-Myers Squibb - have been shown in clinical trials to reduce circulating levels of ANP.

Related topics: Preclinical Research

Follow us

Products

View more

Webinars